Yazar "Tap, Duygu" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    The Effect of Fingolimod (FTY720) Treatment on Liver Enzyme Levels in Relapsing-Remitting Multiple Sclerosis Patients
    (2020) Terzi, Menderes Yusuf; Tap, Duygu; Duman, Taşkın
    Aim: Multiple sclerosis (MS) is a chronic inflammatory pathology affecting the centralnervous system. Many therapeutic options have been approved against MS until today. In thisstudy, it was aimed to investigate the effect of fingolimod treatment (FT) on the liver enzymelevels of relapsing-remitting multiple sclerosis (RRMS) patients.Material and Methods: Body mass index, FT (0.5 mg/day) duration, and liver enzyme(alanine aminotransferase, ALT; gamma glutamyl transferase, GGT) levels of 102 RRMSpatients (66 female, 36 male, mean age was 40.9±10.9 years) were gathered from polyclinicrecords retrospectively.Results: The FT duration of MS patients was between 0.5 and 6 years. Increased ALT andGGT levels were detected in RRMS patients after >3 month-long FT. After FT, ALT and GGTlevels elevated in males almost 2 times higher than in females. It was observed that ALT andGGT levels increased by 1.3 and 1.5 times in females, while 1.6 and 1.9 times in males,respectively. Of the MS patients with increased transaminases post-FT, 7 (23.3%) males and8 (17.4%) females were at upper limit of normal for ALT whereas 9 (34.6%) males and 14(32.6%) females as for GGT. Age and FT duration did not affect ALT and GGT levels.Conclusion: Overall, FT elevated ALT and GGT levels of RRMS patients. Thus, it is of highimportance to monitor MS patients throughout FT. So that, we suggest tracking ALT and GGTlevels during and after FT to prevent possible liver damage or the occurrence of other systemicdiseases.